Niagen Bioscience, Inc. (NAGE) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Niagen Bioscience, Inc. stock (NAGE) is currently trading at $4.54. Niagen Bioscience, Inc. PE ratio is 23.30. Niagen Bioscience, Inc. PS ratio (Price-to-Sales) is 2.88. Analyst consensus price target for NAGE is $13.60. WallStSmart rates NAGE as Sell.
- NAGE PE ratio analysis and historical PE chart
- NAGE PS ratio (Price-to-Sales) history and trend
- NAGE intrinsic value — DCF, Graham Number, EPV models
- NAGE stock price prediction 2025 2026 2027 2028 2029 2030
- NAGE fair value vs current price
- NAGE insider transactions and insider buying
- Is NAGE undervalued or overvalued?
- Niagen Bioscience, Inc. financial analysis — revenue, earnings, cash flow
- NAGE Piotroski F-Score and Altman Z-Score
- NAGE analyst price target and Smart Rating
Niagen Bioscience, Inc.
📊 No data available
Try selecting a different time range
NAGE Intrinsic Value Analysis for Value Investors
Benjamin Graham Formula · Niagen Bioscience, Inc. (NAGE)
NAGE trades 276% above its Graham fair value of $1.36, indicating the stock may be overvalued at current levels.
Based on Benjamin Graham Formula. Growth rate capped at 25%. For informational purposes only. Not financial advice.
Smart Analysis
Niagen Bioscience, Inc. (NAGE) · 9 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in return on equity. Concerns around operating margin and eps growth. Mixed signals suggest waiting for clearer direction before acting.
Niagen Bioscience, Inc. (NAGE) Key Strengths (1)
Every $100 of shareholder equity generates $28 in profit
Supporting Valuation Data
Niagen Bioscience, Inc. (NAGE) Areas to Watch (8)
Earnings declining -41.60%, profits shrinking
Very thin margins with limited operational efficiency
Premium pricing at 4.9x book value
Small-cap company with higher risk but more growth potential
Revenue is fairly priced at 2.88x sales
Solid revenue growth at 16.20% per year
Decent profitability, keeps $13 per $100 revenue
Moderate institutional interest at 41.77%
Niagen Bioscience, Inc. (NAGE) Detailed Analysis Report
Overall Assessment
This company scores 45/100 in our Smart Analysis, earning a D grade. Out of 9 metrics analyzed, 1 register as strengths (avg 10.0/10) while 8 fall into concern territory (avg 4.4/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Return on Equity. Profitability is solid with Return on Equity at 28.30%.
The Bear Case
The primary concerns are EPS Growth, Operating Margin, Price/Book. Some valuation metrics including Price/Sales (2.88), Price/Book (4.88) suggest expensive pricing. Growth concerns include Revenue Growth at 16.20%, EPS Growth at -41.60%, which may limit upside. Profitability pressure is visible in Operating Margin at 6.22%, Profit Margin at 13.40%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether EPS Growth improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at 28.30% currently healthy but needing to be sustained. Third, growth sustainability, with Revenue Growth at 16.20% needing to reaccelerate.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. EPS Growth and Operating Margin are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
NAGE Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
NAGE's Price-to-Sales ratio of 2.88x sits near its historical average of 3.06x (0th percentile), suggesting the market is pricing in steady-state growth. The current valuation is 11% below its historical high of 3.23x set in Mar 2026, and 0% above its historical low of 2.88x in Mar 2026. Over the past 12 months, the PS ratio has compressed from ~3.2x as trailing revenue scaled faster than the stock price.
WallStSmart Analysis Synopsis
Data-driven financial summary for Niagen Bioscience, Inc. (NAGE) · HEALTHCARE › BIOTECHNOLOGY
The Big Picture
Niagen Bioscience, Inc. is a strong growth company balancing expansion with improving profitability. Revenue reached 129M with 16% growth year-over-year. Profit margins of 13.4% are healthy, with room for further expansion as the business scales.
Key Findings
ROE of 28.3% means the company generates strong returns on shareholder equity. Above 20% is considered top-tier.
Generating 523,000 in free cash flow and 624,000 in operating cash flow. Earnings are translating into actual cash generation.
Earnings fell 42% YoY while revenue grew 16%. This gap usually reflects one-time items (tax benefits, write-offs) in the prior period, not an operational decline.
What to Watch Next
Margin expansion: can Niagen Bioscience, Inc. push profit margins above 15% as the business scales?
Volatility is elevated with a beta of 2.23, so expect amplified moves relative to the broader market.
Sector dynamics: monitor BIOTECHNOLOGY industry trends, competitive moves, and regulatory changes that could impact Niagen Bioscience, Inc..
Bottom Line
Niagen Bioscience, Inc. offers an attractive blend of growth (16% revenue expansion) and improving fundamentals. The company is transitioning from pure growth to profitable growth, a critical inflection point. Watch for sustained margin expansion as the key signal.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Loading insider activity...
About Niagen Bioscience, Inc.(NAGE)
NASDAQ
HEALTHCARE
BIOTECHNOLOGY
USA
Niagen Bioscience, Inc. is a bioscience company engages in developing healthy aging products. The company is headquartered in Los Angeles, California.